Pacific Biosciences of California Inc. (PACB)
NASDAQ: PACBIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PACB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $508.95M
- EPS (TTM)
- -$0.42
- Dividend yield
- None
- 52-week range
- 1.07 – 3.44
- Day range
- 1.61 – 1.73
- Volume / Avg
- 13.68M / 13.23M
- Beta
- —
- Shares outstanding
- 312.24M
52-week range
PACB stock today
Shares of Pacific Biosciences of California (PACB) finished lower on Nov 20 at $1.63, a drop of 7.39% or $0.13 per share, versus the S&P 500's 3.70% decline. At this level, PACB sits in the middle of its 52-week range of $1.07 to $3.44: 52.6% below the high, set on Oct 6, 2026 and 52.3% above the low. PACB is down 12.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 26.6%.
Pacific Biosciences of California has posted a net loss over the last twelve months (EPS of -$0.42), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Pacific Biosciences of California
Company profilePacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Mr. Mark Van Oene Ph.D.
- Headquarters
- Menlo Park, CA
- Employees
- 485
- IPO year
- 2010
- Website
- pacb.com
Financial highlights
Full financialsIn fiscal 2025, Pacific Biosciences of California generated $160.0 million in revenue, up 3.9% from fiscal 2024. Pacific Biosciences of California reported a net loss of $546.4 million, compared with a loss of $309.9 million a year earlier. Gross margin was 28.6% (up from 24.2%) and operating margin -346.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $160.00M | $154.01M | $200.52M | $128.30M | $130.51M |
| Growth | +3.89% | -23.19% | +56.29% | -1.69% | +65.43% |
| Net income | $-546.38M | $-309.85M | $-306.74M | $-314.25M | $-181.22M |
| EPS (diluted) | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 |
Analyst forecast
ForecastConsensus (8 analysts)
buy
Avg. price target
$2.74+68.10%
- Strong buy 0
- Buy 4
- Hold 3
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.12 vs $-0.13
- Surprise
- +7.69%
PACB news
All PACB news- PacBio to Participate in the Piper Sandler 38th Annual Healthcare ConferenceGlobeNewswire
- Pacific Biosciences of California Consensus Price Target Raised 16.37% to $2.85Nasdaq
- PacBio (PACB) Q3 2026 Earnings Call TranscriptNasdaq
- Pacific Biosciences of California, Inc. Announces CFO Transition and Reports Q3 2026 Financial ResultsNasdaq
- Pacific Biosciences of California Non-GAAP EPS of -$0.11 beats by $0.02, revenue of $40.6M beats by $1.14MSeeking Alpha
- Glaukos (GKOS) Q3 Earnings and Revenues Surpass EstimatesNasdaqGKOS, PACB
- Wednesday's ETF Movers: ARKG, EISNasdaqPACB, CHKP, ETOR, EIS
- PacBio to Participate in Upcoming Investor ConferencesGlobeNewswire
Pacific Biosciences of California peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NAUTNautilus Biotechnology Inc. | 2.12 | -2.30% | $270.03M | vs PACB |
| LABStandard BioTools Inc. | 0.631 | +2.82% | $249.11M | vs PACB |
| CTKBCytek Biosciences Inc. | 6.12 | -3.16% | $800.40M | vs PACB |
| QTRXQuanterix Corporation | 1.96 | -3.45% | $93.06M | vs PACB |
| SEERSeer Inc. Class A | 1.36 | -1.81% | $75.91M | vs PACB |
| HBIOHarvard Bioscience Inc. | 8.66 | -0.23% | $39.60M | vs PACB |
| RPIDRapid Micro Biosystems Inc. Class A | 0.735 | -0.04% | $37.37M | vs PACB |
| PRPOPrecipio Inc. | 17.35 | -6.17% | $31.11M | vs PACB |
Indexes, lists and sector
Pacific Biosciences of California stock FAQ
What is Pacific Biosciences of California's stock price today?
PACB last traded at $1.63 as of Nov 20, 4:00 PM EST, down 7.39% on the day. Prices are delayed at least 15 minutes.
Who is Pacific Biosciences of California's CEO?
Mr. Mark Van Oene Ph.D. is the chief executive officer of Pacific Biosciences of California Inc., which has about 485 employees.
What is the PACB 52-week high?
The 52-week high for PACB is $3.44 and the 52-week low is $1.07. The stock is currently 52.6% below its high.